Biosimilars in the United States: Emerging Issues in Litigation

Area of Science:

• Pharmaceutical Sciences
• Health Economics
• Regulatory Affairs

Background:

• First-generation biologics are nearing patent expiration, opening opportunities for biosimilars.
• The United States represents a critical, yet challenging, market for biosimilar products.
• Market entry for biosimilars is hindered by regulatory uncertainty and complex patent resolution.

Purpose of the Study:

• To review the US regulatory framework for biosimilar products under the Biologics Price Control and Innovation Act (BPCIA).
• To analyze emerging issues in the biosimilar litigation landscape.
• To provide recommendations for companies navigating the US biosimilars market.

Main Methods:

• Review of the US regulatory framework for biosimilars.
• Analysis of patent issues and litigation trends under the BPCIA.
• Examination of market access barriers including trade secrets and exclusivity.

Main Results:

• Unclear regulatory requirements and patent procedures pose significant hurdles.
• Limited market exclusivity and adoption, along with trade secret concerns, impact market access.
• Navigating the complex regulatory and litigation environment is crucial for success.

Conclusions:

• Companies must closely monitor the evolving regulatory and litigation landscape.
• Strategic understanding of the BPCIA and patent strategies is essential for biosimilar developers.
• Recommendations are provided to facilitate market entry and success in the US biosimilars market.